The RNA-binding protein FXR1 modulates prostate cancer progression by regulating FBXO4
This paper is to characterize the expression status of Fragile X Mental Retardation, Autosomal Homolog 1 (FXR1) in prostate cancer cells and understand its mechanistic involvement in the tumor biology of prostate cancer. The relative expression of FXR1 in prostate cancer cells was determined by real-time polymerase chain reaction and Western blotting. Cell proliferation in FXR1-deficient cells was evaluated by cell counting and MTT assays. The migrative and invasive capacities were measured by transwell assay. The potential regulatory effect of FXR1 on FBXO4 was interrogated using luciferase reporter assay. The direct bind of FXR1 with FBXO4 transcripts was analyzed by RNA immunoprecipitation and RNA pull-down assay. We observed aberrant overexpression of FXR1 in prostate cancer cells at both transcript and protein levels. FXR1 deficiency was associated with inhibited cell proliferation/viability and compromised migration/invasion in prostate cancer cells. Mechanistically, FXR1 negatively regulated FBXO4 transcripts via direct association with its 3′UTR and promoted mRNA degradation. FBXO4 knockdown predominantly rescued the tumor-suppressive phenotype in FXR1-deficient cells. We uncovered the oncogenic role of FXR1 in prostate cancer cells and further demonstrated its dependence on FBXO4. Our data highlight the importance of FXR1-FBXO4 signaling in prostate cancer.
KeywordsFXR1 FBXO4 Prostate cancer Migration Stability
This study was supported by The third batch of young Chinese name training program of LongHua Hospital Shanghai University of Traditional Chinese Medicine (Chen Lei, RC-2017-01-14); Shanghai Municipal Health and Family Planning Commission special subject of Chinese medicine research (2016JP014); National TCM clinical research base dragon medicine scholars (nursery plan) of LONGHUA Hospital Shanghai University of Traditional Chinese Medicine (LYTD-56); Shanghai School of Traditional Chinese Medicine Shanghai Inheritance Talents Training Project (LPRC-2017-015).
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
Research involving human participants and/or animals
This article does not contain any studies with human participants or animals performed by any of the authors.
- Comtesse N, Keller A, Diesinger I, Bauer C, Kayser K, Huwer H, Lenhof HP, Meese E (2007) Frequent overexpression of the genes FXR1, CLAPM1 and EIF4G located on amplicon 3q26-27 in squamous cell carcinoma of the lung. Int J Cancer 120:2538–2544. https://doi.org/10.1002/ijc.22585 CrossRefGoogle Scholar
- Fan Y, Yue J, Xiao M, Han-Zhang H, Wang YV, Ma C, Deng Z, Li Y, Yu Y, Wang X, Niu S, Hua Y, Weng Z, Atadja P, Li E, Xiang B (2017) FXR1 regulates transcription and is required for growth of human cancer cells with TP53/FXR2 homozygous deletion. Elife 6. https://doi.org/10.7554/eLife.26129
- Lee EK, Lian Z, D’Andrea K, Letrero R, Sheng W, Liu S, Diehl JN, Pytel D, Barbash O, Schuchter L, Amaravaradi R, Xu X, Herlyn M, Nathanson KL, Diehl JA (2013) The FBXO4 tumor suppressor functions as a barrier to BRAFV600E-dependent metastatic melanoma. Mol Cell Biol 33:4422–4433. https://doi.org/10.1128/MCB.00706-13 CrossRefPubMedCentralGoogle Scholar
- Qian J, Hassanein M, Hoeksema MD, Harris BK, Zou Y, Chen H, Lu P, Eisenberg R, Wang J, Espinosa A, Ji X, Harris FT, Rahman SM, Massion PP (2015) The RNA binding protein FXR1 is a new driver in the 3q26-29 amplicon and predicts poor prognosis in human cancers. Proc Natl Acad Sci U S A 112:3469–3474. https://doi.org/10.1073/pnas.1421975112 CrossRefPubMedCentralGoogle Scholar
- Qian J, Chen H, Ji X, Eisenberg R, Chakravarthy AB, Mayer IA, Massion PP (2017) A 3q gene signature associated with triple negative breast cancer organ specific metastasis and response to neoadjuvant chemotherapy. Sci Rep 7:45828. https://doi.org/10.1038/srep45828 CrossRefPubMedCentralGoogle Scholar
- Schenck A, Bardoni B, Moro A, Bagni C, Mandel JL (2001) A highly conserved protein family interacting with the fragile X mental retardation protein (FMRP) and displaying selective interactions with FMRP-related proteins FXR1P and FXR2P. Proc Natl Acad Sci U S A 98:8844–8849. https://doi.org/10.1073/pnas.151231598 CrossRefPubMedCentralGoogle Scholar
- Zhao BB, Yang ZJ, Wang Q, Pan ZM, Zhang W, Li L (2017) [Clinical validation of multiple biomarkers suspension array technology for ovarian cancer]. Zhonghua Fu Chan Ke Za Zhi 52:11–19. https://doi.org/10.3760/cma.j.issn.0529-567X.2017.01.005 Google Scholar